Literature DB >> 27514465

Pharmacogenomics in Psychiatric Practice.

Rif S El-Mallakh1, R Jeannie Roberts2, Peggy L El-Mallakh3, Lillian Jan Findlay3, Kristen K Reynolds4.   

Abstract

Pharmacogenomic testing in psychiatry is becoming an established clinical procedure. Several vendors provide clinical interpretation of combinatorial pharmacogenomic testing of gene variants that have documented predictive implications regarding either pharmacologic response or adverse effects in depression and other psychiatric conditions. Such gene profiles have demonstrated improvements in outcome in depression, and reduction of cost of care of patients with inadequate clinical response. Additionally, several new gene variants are being studied to predict specific response in individuals. Many of these genes have demonstrated a role in the pathophysiology of depression or specific depressive symptoms. This article reviews the current state-of-the-art application of psychiatric pharmacogenomics.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  2D6; Antidepressants; Antipsychotics; CYP2D6; OPRM1; Pharmacogenomic testing; Psychiatric pharmacogenomics; SLC6A4

Mesh:

Year:  2016        PMID: 27514465     DOI: 10.1016/j.cll.2016.05.001

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  3 in total

Review 1.  Pharmacogenomic Biomarkers and Their Applications in Psychiatry.

Authors:  Heejin Kam; Hotcherl Jeong
Journal:  Genes (Basel)       Date:  2020-11-30       Impact factor: 4.096

Review 2.  Novel treatment options in depression and psychosis.

Authors:  Eva Ceskova; Petr Silhan
Journal:  Neuropsychiatr Dis Treat       Date:  2018-03-13       Impact factor: 2.570

3.  Asenapine in the Treatment of Bipolar Depression.

Authors:  Rif S El-Mallakh; Sharon Nuss; Dong Gao; Yonglin Gao; Surriya Colleen Ahmad; Clare Schrodt; Caleb Adler
Journal:  Psychopharmacol Bull       Date:  2020-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.